NR4A1 and hepatocellular carcinoma: We identified the first Nur77 agonist, Cytosporone-B (Csn-B).19 On the basis of the framework of Csn-B, additional chemical compounds that target Nur77 but have different functions were discovered by our group, including TMPA, which can decrease glucose levels by regulating AMPK,20 and PDNPA, which not only has anti-inflammatory properties by modulating p38 phosphorylation21 but also has an inhibitory effect on the progression of hepatocellular carcinoma via ectosomes.22 Clearly, Nur77 is a viable target for modulating physiological and pathological processes.